{
  "parsed": [
    {
      "model": "claude",
      "raw": "\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-questions:**\n1. How does mitochondrial membrane potential (\u0394\u03a8m) cycle circadianly, and what is the amplitude of oscillation around the -180 mV baseline?\n2. How does \u0394\u03a8m (or derived OMM voltage) modulate VDAC1 gating state, and does CBD binding affinity/mode differ between open vs. closed conformations?\n3. At what \u0394\u03a8m does CBD's interaction with VDAC1 shift from metabolite-flux modulation (cytoprotective) to oligomerization-driven cytochrome c release (cytotoxic)?\n4. Do circadian variations in VDAC1 expression, post-translational modification, or interacting partners (hexokinase, tubulin) independently modulate this threshold?\n\n**Key variables:** \u0394\u03a8m oscillation amplitude (~15-20 mV), VDAC1 open probability as f(voltage), CBD concentration relative to Kd (11 \u03bcM), VDAC1 oligomerization kinetics, circadian phase of DRP1/mitochondrial fission machinery.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM 1:** Circadian \u0394\u03a8m oscillates with amplitude ~15-20 mV (trough ~-160 to -165 mV during late rest phase, peak ~-180 mV during active phase), driven by clock-controlled expression of ETC complex subunits and UCP2/3.\n**TYPE:** 2 | **CONFIDENCE:** 0.6\n**MECHANISM:** BMAL1/CLOCK drive rhythmic transcription of NAMPT\u2192NAD+ cycling, which modulates Complex I activity and proton pumping efficiency.\n**FALSIFIABLE BY:** TMRM/JC-1 live imaging of \u0394\u03a8m across 24h in SCN-synchronized cells with and without BMAL1 knockout.\n\n**CLAIM 2:** VDAC1 gating responds to OMM voltage (not \u0394\u03a8m directly); at depolarized \u0394\u03a8m (~-160 mV), reduced Donnan potential across IMS keeps VDAC1 in high-conductance open state, where CBD binds the open pore without inducing oligomerization\u2014this is the cytoprotective regime.\n**TYPE:** 2 | **CONFIDENCE:** 0.55\n**MECHANISM:** Open VDAC1 permits CBD to modulate metabolite flux (enhancing ATP/ADP exchange) without the conformational strain that closed-state dimers/oligomers impose.\n**FALSIFIABLE BY:** Electrophysiology of reconstituted VDAC1 \u00b1 CBD at controlled voltages, measuring single-channel conductance and oligomer crosslinking simultaneously.\n\n**CLAIM 3:** The cytotoxic transition occurs NOT at depolarized \u0394\u03a8m but at **hyperpolarized** \u0394\u03a8m (~-180 mV), where VDAC1 partial closure promotes oligomerization; CBD at \u22655 \u03bcM stabilizes closed-state oligomeric pores, enabling cytochrome c release. The established consensus (depolarized = toxic) may be inverted.\n**TYPE:** 3 | **CONFIDENCE:** 0.45\n**MECHANISM:** Closed VDAC1 exposes oligomerization interfaces (\u03b2-strands 1,2,19); CBD's hydrophobic intercalation between monomers stabilizes hexameric pores large enough for cytochrome c (~12 kDa) passage.\n**FALSIFIABLE BY:** CBD dose-response curves for apoptosis in cells with \u0394\u03a8m clamped to -150 mV vs. -180 mV using ionophores; if cytotoxicity is higher at -180 mV, this claim holds.\n\n**CLAIM 4:** Circadian hexokinase-II dissociation from VDAC1 (regulated by GSK3\u03b2/AKT cycling) is the dominant modulator of CBD's therapeutic window, more than \u0394\u03a8m per se.\n**TYPE:** 3 | **CONFIDENCE:** 0.35\n**MECHANISM:** HK-II binding occludes CBD's VDAC1 binding site; circadian AKT activity peaks drive HK-II association, creating a time window where CBD cannot access VDAC1.\n**FALSIFIABLE BY:** CBD-VDAC1 FRET signal \u00b1 HK-II overexpression across circadian timepoints.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\n\n- **Critical gap:** No direct measurement of circadian \u0394\u03a8m amplitude in any mammalian cell type with sufficient temporal resolution.\n- Whether CBD binds preferentially to open or closed VDAC1 (no structural data for CBD-VDAC1 complex exists).\n- The Rimmerman Kd (11 \u03bcM) was measured without voltage control\u2014true voltage-dependent Kd is unknown.\n- Circadian regulation of V",
      "claims": [
        {
          "statement": "1:** Circadian \u0394\u03a8m oscillates with amplitude ~15-20 mV (trough ~-160 to -165 mV during late rest phase, peak ~-180 mV during active phase), driven by clock-controlled expression of ETC complex subunits and UCP2/3.",
          "type": 2,
          "confidence": 0.6,
          "mechanism": "BMAL1/CLOCK drive rhythmic transcription of NAMPT\u2192NAD+ cycling, which modulates Complex I activity and proton pumping efficiency.",
          "falsifiable_by": "TMRM/JC-1 live imaging of \u0394\u03a8m across 24h in SCN-synchronized cells with and without BMAL1 knockout."
        },
        {
          "statement": "2:** VDAC1 gating responds to OMM voltage (not \u0394\u03a8m directly); at depolarized \u0394\u03a8m (~-160 mV), reduced Donnan potential across IMS keeps VDAC1 in high-conductance open state, where CBD binds the open pore without inducing oligomerization\u2014this is the cytoprotective regime.",
          "type": 2,
          "confidence": 0.55,
          "mechanism": "Open VDAC1 permits CBD to modulate metabolite flux (enhancing ATP/ADP exchange) without the conformational strain that closed-state dimers/oligomers impose.",
          "falsifiable_by": "Electrophysiology of reconstituted VDAC1 \u00b1 CBD at controlled voltages, measuring single-channel conductance and oligomer crosslinking simultaneously."
        },
        {
          "statement": "3:** The cytotoxic transition occurs NOT at depolarized \u0394\u03a8m but at **hyperpolarized** \u0394\u03a8m (~-180 mV), where VDAC1 partial closure promotes oligomerization; CBD at \u22655 \u03bcM stabilizes closed-state oligomeric pores, enabling cytochrome c release. The established consensus (depolarized = toxic) may be inverted.",
          "type": 3,
          "confidence": 0.45,
          "mechanism": "Closed VDAC1 exposes oligomerization interfaces (\u03b2-strands 1,2,19); CBD's hydrophobic intercalation between monomers stabilizes hexameric pores large enough for cytochrome c (~12 kDa) passage.",
          "falsifiable_by": "CBD dose-response curves for apoptosis in cells with \u0394\u03a8m clamped to -150 mV vs. -180 mV using ionophores; if cytotoxicity is higher at -180 mV, this claim holds."
        },
        {
          "statement": "4:** Circadian hexokinase-II dissociation from VDAC1 (regulated by GSK3\u03b2/AKT cycling) is the dominant modulator of CBD's therapeutic window, more than \u0394\u03a8m per se.",
          "type": 3,
          "confidence": 0.35,
          "mechanism": "HK-II binding occludes CBD's VDAC1 binding site; circadian AKT activity peaks drive HK-II association, creating a time window where CBD cannot access VDAC1.",
          "falsifiable_by": "CBD-VDAC1 FRET signal \u00b1 HK-II overexpression across circadian timepoints. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "---\n**SECTION 1: DECOMPOSITION**\n1. **How does circadian \u0394\u03a8m cycling (e.g., -180 mV to -160 mV) alter VDAC1 gating state (open/closed/oligomerized)?**\n   *Key variables*: \u0394\u03a8m, VDAC1 conductance, voltage-dependent gating kinetics.\n2. **Does CBD binding affinity (Kd = 11 \u03bcM) or cooperativity (Hill coefficient) change with VDAC1 gating state?**\n   *Key variables*: CBD concentration, VDAC1 conformation, cyt c release threshold.\n3. **What \u0394\u03a8m-dependent mechanisms govern the transition from cytoprotection (TRPV1/2-mediated) to cytotoxicity (VDAC1-mediated)?**\n   *Key variables*: TRPV1/2 Kd (2\u20133.7 \u03bcM), VDAC1 oligomerization, apoptotic threshold.\n4. **Is the cytotoxic threshold (IC50) for CBD time-of-day dependent, and does it correlate with \u0394\u03a8m troughs (e.g., nighttime)?**\n   *Key variables*: IC50 shift (3\u20135x), circadian \u0394\u03a8m rhythm, sub-Kd toxicity.\n\n---\n\n**SECTION 2: CLAIMS**\n\n**CLAIM 1**: Circadian \u0394\u03a8m depolarization (e.g., -160 mV nighttime) reduces CBD\u2019s cytotoxic threshold to **3\u20135 \u03bcM (sub-Kd)**, while hyperpolarization (-180 mV daytime) raises it to **15\u201320 \u03bcM**.\n**TYPE**: 1 (refines prior convergence)\n**CONFIDENCE**: 0.7\n**MECHANISM**: Depolarized \u0394\u03a8m increases VDAC1 open probability, enhancing CBD binding cooperativity (Hill >1) and accelerating oligomerization-driven cyt c release.\n**FALSIFIABLE BY**: Measuring CBD IC50 in cells with \u0394\u03a8m clamped to -160 mV vs. -180 mV using FCCP/oligomycin.\n\n**CLAIM 2**: VDAC1\u2019s open probability peaks at **-170 mV** and declines linearly to **50% at -150 mV**, with closure promoting oligomerization.\n**TYPE**: 2 (novel prediction)\n**CONFIDENCE**: 0.6\n**MECHANISM**: The N-terminal \u03b1-helix of VDAC1 acts as a voltage sensor, blocking the pore at depolarized potentials (consistent with *mistral*\u2019s singular claim).\n**FALSIFIABLE BY**: Patch-clamp recordings of VDAC1 in proteoliposomes at -140 mV vs. -180 mV, or cryo-EM structures under these conditions.\n\n**CLAIM 3**: Cytoprotective CBD effects (via TRPV1/2, Kd 2\u20133.7 \u03bcM) dominate at **\u0394\u03a8m > -170 mV**, while cytotoxic effects (VDAC1-mediated) emerge at **\u0394\u03a8m < -160 mV** due to oligomerization.\n**TYPE**: 1 (integrates singular threads)\n**CONFIDENCE**: 0.65\n**MECHANISM**: Hyperpolarized \u0394\u03a8m favors VDAC1 closure, limiting CBD access to oligomerization sites, while TRPV1/2 remain active at lower CBD concentrations.\n**FALSIFIABLE BY**: Super-resolution microscopy of VDAC1 oligomers in cells treated with CBD at clamped \u0394\u03a8m (-150 mV vs. -170 mV).\n\n**CLAIM 4**: The outer mitochondrial membrane (OMM) voltage\u2014modulated by \u0394\u03a8m via Donnan equilibrium\u2014directly gates VDAC1, with depolarized \u0394\u03a8m reducing OMM voltage and favoring VDAC1\u2019s open state.\n**TYPE**: 2 (mechanistic refinement)\n**CONFIDENCE**: 0.55\n**MECHANISM**: \u0394\u03a8m depolarization decreases the intermembrane space potential, lowering OMM voltage and stabilizing VDAC1\u2019s anion-permeable open conformation.\n**FALSIFIABLE BY**: Simultaneous measurements of \u0394\u03a8m (TMRM) and OMM voltage (OMM-targeted voltage sensors) in cells under circadian \u0394\u03a8m cycling.\n\n---\n\n**SECTION 3: UNKNOWNS**\n1. **Quantitative relationship between \u0394\u03a8m and OMM voltage**: How does \u0394\u03a8m depolarization (e.g., -180 mV \u2192 -160 mV) translate to OMM voltage changes? Missing: direct OMM voltage measurements under physiological \u0394\u03a8m.\n2. **VDAC1 oligomerization kinetics**: Does CBD binding accelerate oligomerization at depolarized \u0394\u03a8m, or is oligomerization purely voltage-dependent? Missing: time-resolved oligomerization assays (e.g., FRET) with CBD titration.\n3. **Circadian \u0394\u03a8m amplitude in vivo**: Are \u0394\u03a8m troughs (-160 mV) physiologically relevant in neurons, or is this an artifact of in vitro models? Missing: longitudinal \u0394\u03a8m recordings in SCN neurons or peripheral clocks.\n4. **TRPV1/2 vs. VDAC1 crosstalk**: Do TRPV1/2-mediated Ca\u00b2\u207a influx or metabolic shifts (e.g., ATP/ADP ratio) indirectly modulate VDAC1 gating? Missing:",
      "claims": [
        {
          "statement": "1**: Circadian \u0394\u03a8m depolarization (e.g., -160 mV nighttime) reduces CBD\u2019s cytotoxic threshold to **3\u20135 \u03bcM (sub-Kd)**, while hyperpolarization (-180 mV daytime) raises it to **15\u201320 \u03bcM**. **TYPE**: 1 (refines prior convergence) **CONFIDENCE**: 0.7 **MECHANISM**: Depolarized \u0394\u03a8m increases VDAC1 open probability, enhancing CBD binding cooperativity (Hill >1) and accelerating oligomerization-driven cyt c release. **FALSIFIABLE BY**: Measuring CBD IC50 in cells with \u0394\u03a8m clamped to -160 mV vs. -180 mV using FCCP/oligomycin.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Depolarized \u0394\u03a8m increases VDAC1 open probability, enhancing CBD binding cooperativity (Hill >1) and accelerating oligomerization-driven cyt c release.",
          "falsifiable_by": ": Measuring CBD IC50 in cells with \u0394\u03a8m clamped to -160 mV vs. -180 mV using FCCP/oligomycin."
        },
        {
          "statement": "2**: VDAC1\u2019s open probability peaks at **-170 mV** and declines linearly to **50% at -150 mV**, with closure promoting oligomerization. **TYPE**: 2 (novel prediction) **CONFIDENCE**: 0.6 **MECHANISM**: The N-terminal \u03b1-helix of VDAC1 acts as a voltage sensor, blocking the pore at depolarized potentials (consistent with *mistral*\u2019s singular claim). **FALSIFIABLE BY**: Patch-clamp recordings of VDAC1 in proteoliposomes at -140 mV vs. -180 mV, or cryo-EM structures under these conditions.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": The N-terminal \u03b1-helix of VDAC1 acts as a voltage sensor, blocking the pore at depolarized potentials (consistent with *mistral*\u2019s singular claim).",
          "falsifiable_by": ": Patch-clamp recordings of VDAC1 in proteoliposomes at -140 mV vs. -180 mV, or cryo-EM structures under these conditions."
        },
        {
          "statement": "3**: Cytoprotective CBD effects (via TRPV1/2, Kd 2\u20133.7 \u03bcM) dominate at **\u0394\u03a8m > -170 mV**, while cytotoxic effects (VDAC1-mediated) emerge at **\u0394\u03a8m < -160 mV** due to oligomerization. **TYPE**: 1 (integrates singular threads) **CONFIDENCE**: 0.65 **MECHANISM**: Hyperpolarized \u0394\u03a8m favors VDAC1 closure, limiting CBD access to oligomerization sites, while TRPV1/2 remain active at lower CBD concentrations. **FALSIFIABLE BY**: Super-resolution microscopy of VDAC1 oligomers in cells treated with CBD at clamped \u0394\u03a8m (-150 mV vs. -170 mV).",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Hyperpolarized \u0394\u03a8m favors VDAC1 closure, limiting CBD access to oligomerization sites, while TRPV1/2 remain active at lower CBD concentrations.",
          "falsifiable_by": ": Super-resolution microscopy of VDAC1 oligomers in cells treated with CBD at clamped \u0394\u03a8m (-150 mV vs. -170 mV)."
        },
        {
          "statement": "4**: The outer mitochondrial membrane (OMM) voltage\u2014modulated by \u0394\u03a8m via Donnan equilibrium\u2014directly gates VDAC1, with depolarized \u0394\u03a8m reducing OMM voltage and favoring VDAC1\u2019s open state. **TYPE**: 2 (mechanistic refinement) **CONFIDENCE**: 0.55 **MECHANISM**: \u0394\u03a8m depolarization decreases the intermembrane space potential, lowering OMM voltage and stabilizing VDAC1\u2019s anion-permeable open conformation. **FALSIFIABLE BY**: Simultaneous measurements of \u0394\u03a8m (TMRM) and OMM voltage (OMM-targeted voltage sensors) in cells under circadian \u0394\u03a8m cycling. ---",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": \u0394\u03a8m depolarization decreases the intermembrane space potential, lowering OMM voltage and stabilizing VDAC1\u2019s anion-permeable open conformation.",
          "falsifiable_by": ": Simultaneous measurements of \u0394\u03a8m (TMRM) and OMM voltage (OMM-targeted voltage sensors) in cells under circadian \u0394\u03a8m cycling. --- **"
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 \nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\nSub-questions:  \n1. Does mitochondrial \u0394\u03a8m cycle circadianly (amplitude ~10-20 mV, e.g., -180 mV day hyperpolarized to -165 mV night depolarized), and does this align with cytoprotective windows?  \n2. How does \u0394\u03a8m modulate VDAC1 gating (P_open >80% depolarized vs <30% hyperpolarized), influencing CBD binding/oligomerization?  \n3. Does this shift CBD dose-response (cytoprotective EC50 ~3 \u03bcM via TRPV1/2 daytime; cytotoxic IC50 3-5 \u03bcM vs 15 \u03bcM nighttime via VDAC1 Kd 11 \u03bcM)?  \nKey variables/relationships: \u0394\u03a8m \u2194 VDAC1 P_open (Donnan-mediated, depolarized \u2192 open \u2192 low IC50); CBD [ ] threshold (sub-Kd cytotoxicity when open); circadian phase \u2192 metabolic fluxes \u2192 \u0394\u03a8m.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: Circadian depolarized \u0394\u03a8m (-165 mV nighttime) lowers CBD cytotoxic IC50 3-5x (to 3-5 \u03bcM from 15 \u03bcM daytime), enabling sub-Kd (11 \u03bcM) toxicity via VDAC1.  \nTYPE: 2  \nCONFIDENCE: 0.72  \nMECHANISM: Depolarized \u0394\u03a8m favors VDAC1 open state (P_open >80%), enhancing CBD binding cooperativity (Hill n>1.5) and oligomerization for cyt c release.  \nFALSIFIABLE BY: Circadian-synchronized cells show no IC50 shift (MTT/LDH assay) when \u0394\u03a8m clamped (oligomycin/FCCP) at peaks/troughs.\n\nCLAIM: VDAC1 P_open >80% at depolarized \u0394\u03a8m (>-160 mV) vs <30% at hyperpolarized (<-170 mV), validating grok singular, rejecting mistral inversion.  \nTYPE: 2  \nCONFIDENCE: 0.81  \nMECHANISM: \u0394\u03a8m influences OMM voltage via Donnan equilibrium; depolarization reduces |OMM V|, preventing N-terminal helix pore block (claude singular overlap).  \nFALSIFIABLE BY: Proteoliposome patch-clamp of VDAC1 under mimicked \u0394\u03a8m (-150 vs -180 mV) shows inverted P_open.\n\nCLAIM: Cytoprotective CBD (EC50 2-3.7 \u03bcM via TRPV1/2) dominates daytime (hyperpolarized \u03c8 closes VDAC1, blocking cytotoxicity); nighttime flip via open VDAC1.  \nTYPE: 1  \nCONFIDENCE: 0.68  \nMECHANISM: Low-dose CBD modulates Ca2+/metabolite flux protectively; VDAC1 closure at -180 mV requires >Kd CBD for forced oligomerization.  \nFALSIFIABLE BY: TRPV1/2 KO cells show no daytime protection but retain nighttime cytotoxicity shift.\n\nCLAIM: Threshold transition at \u0394\u03a8m \u2248 -165 mV, where VDAC1 P_open >50% enables CBD-stabilized hexameric pores for apoptosis.  \nTYPE: 3  \nCONFIDENCE: 0.55  \nMECHANISM: Partial depolarization shifts VDAC1 to metastable open, where sub-Kd CBD binds cooperatively, exceeding oligomer threshold (refines mistral/claude).  \nFALSIFIABLE BY: Super-res microscopy of VDAC1 oligomers in CBD-treated cells at \u0394\u03a8m -160 mV vs -170 mV shows no hexamer increase.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\nMissing: Neuronal mitochondrial \u0394\u03a8m circadian waveform (precise amplitude/phase via PER2-luc + TMRE). In vivo CBD-VDAC1 binding affinities at voltage-clamped mito. VDAC1 oligomer stoichiometry threshold for cyt c release. Clock gene (BMAL1) effects on VDAC1 acetylation/SIRT3. Would change answer: data showing no \u0394\u03a8m-IC50 correlation, or VDAC1 insensitive to \u0394\u03a8m in Donnan model.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nCircadian-synchronized neurons: TMRE \u0394\u03a8m + CBD dose-response (LDH) at ZT6/18; VDAC1 patch-clamp in voltage-mimicked proteoliposomes.\n\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550",
      "claims": [
        {
          "statement": "Circadian depolarized \u0394\u03a8m (-165 mV nighttime) lowers CBD cytotoxic IC50 3-5x (to 3-5 \u03bcM from 15 \u03bcM daytime), enabling sub-Kd (11 \u03bcM) toxicity via VDAC1.",
          "type": 2,
          "confidence": 0.72,
          "mechanism": "Depolarized \u0394\u03a8m favors VDAC1 open state (P_open >80%), enhancing CBD binding cooperativity (Hill n>1.5) and oligomerization for cyt c release.",
          "falsifiable_by": "Circadian-synchronized cells show no IC50 shift (MTT/LDH assay) when \u0394\u03a8m clamped (oligomycin/FCCP) at peaks/troughs."
        },
        {
          "statement": "VDAC1 P_open >80% at depolarized \u0394\u03a8m (>-160 mV) vs <30% at hyperpolarized (<-170 mV), validating grok singular, rejecting mistral inversion.",
          "type": 2,
          "confidence": 0.81,
          "mechanism": "\u0394\u03a8m influences OMM voltage via Donnan equilibrium; depolarization reduces |OMM V|, preventing N-terminal helix pore block (claude singular overlap).",
          "falsifiable_by": "Proteoliposome patch-clamp of VDAC1 under mimicked \u0394\u03a8m (-150 vs -180 mV) shows inverted P_open."
        },
        {
          "statement": "Cytoprotective CBD (EC50 2-3.7 \u03bcM via TRPV1/2) dominates daytime (hyperpolarized \u03c8 closes VDAC1, blocking cytotoxicity); nighttime flip via open VDAC1.",
          "type": 1,
          "confidence": 0.68,
          "mechanism": "Low-dose CBD modulates Ca2+/metabolite flux protectively; VDAC1 closure at -180 mV requires >Kd CBD for forced oligomerization.",
          "falsifiable_by": "TRPV1/2 KO cells show no daytime protection but retain nighttime cytotoxicity shift."
        },
        {
          "statement": "Threshold transition at \u0394\u03a8m \u2248 -165 mV, where VDAC1 P_open >50% enables CBD-stabilized hexameric pores for apoptosis.",
          "type": 3,
          "confidence": 0.55,
          "mechanism": "Partial depolarization shifts VDAC1 to metastable open, where sub-Kd CBD binds cooperatively, exceeding oligomer threshold (refines mistral/claude).",
          "falsifiable_by": "Super-res microscopy of VDAC1 oligomers in CBD-treated cells at \u0394\u03a8m -160 mV vs -170 mV shows no hexamer increase. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Circadian depolarized \u0394\u03a8m lowers CBD cytotoxic threshold by 3-5x (IC50 from 15 \u03bcM daytime to 3-5 \u03bcM nighttime), enabling sub-Kd (11 \u03bcM) toxicity.\n    MECHANISM: Open VDAC1 at depolarized \u03c8 enhances CBD access/binding cooperativity (Hill coeff >1), accelerating oligomerization and cyt c release.\n    OVERLAP: 5/5 mirrors | CONFIDENCE: 0.581\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] VDAC1 is predominantly open (>80% conductance) at depolarized \u0394\u03a8m (>-160 mV), shifting to closed/low-conductance (<20%) at hyperpolarized (<-170 mV); singular \"grok\" claim validated, \"gemini\" inverted and rejected.\n    SOURCE: grok | CONFIDENCE: 0.9\n  [SINGULAR] Cytoprotective CBD effects (via TRPV1/2, Kd 2-3.7 \u03bcM) dominate at hyperpolarized daytime \u03c8; cytotoxic via VDAC1 flips at depolarized nighttime.\n    SOURCE: grok | CONFIDENCE: 0.65\n  [SINGULAR] VDAC1's voltage-dependent gating operates on **outer mitochondrial membrane (OMM) voltage**, not \u0394\u03a8m directly; however, \u0394\u03a8m influences OMM voltage via the Donnan equilibrium across the intermembrane space. Depolarized \u0394\u03a8m reduces OMM voltage, favoring VDAC1 open state (anion-permeable), while hyperpolarized \u0394\u03a8m increases OMM voltage, promoting VDAC1 closure and oligomerization.\n    SOURCE: claude | CONFIDENCE: 0.55\n  [SINGULAR] At depolarized \u0394\u03a8m (trough, ~-165 mV), VDAC1 remains predominantly open, and CBD at sub-Kd concentrations acts cytoprotectively by modulating metabolite flux (ATP/ADP exchange) without triggering oligomerization.\n    SOURCE: claude | CONFIDENCE: 0.5\n  [SINGULAR] 2**: VDAC1\u2019s open probability is **maximal at \u0394\u03a8m = -180 mV** and decreases linearly with depolarization, reaching 50% closure at **~ -150 mV**. **TYPE**: 2 (novel, testable prediction) **CONFIDENCE**: 0.65 **MECHANISM**: VDAC1\u2019s N-terminal \u03b1-helix acts as a voltage sensor, blocking the pore at depolarized potentials (consistent with [SINGULAR] voltage-sensitive gating). **FALSIFIABLE BY**: Patch-clamp recordings of VDAC1 in proteoliposomes under varying \u0394\u03a8m, or cryo-EM structures at -140 mV vs. -180 mV.\n    SOURCE: mistral | CONFIDENCE: 0.5\n  [SINGULAR] 4**: The transition from cytoprotective to cytotoxic CBD effects occurs at **\u0394\u03a8m < -160 mV**, where VDAC1 oligomerization exceeds a critical threshold (e.g., hexamers). **TYPE**: 3 (speculative, quantitative prediction) **CONFIDENCE**: 0.5 **MECHANISM**: Below -160 mV, VDAC1\u2019s voltage-dependent closure promotes oligomerization, enabling CBD to stabilize large pores and trigger apoptosis. **FALSIFIABLE BY**: Super-resolution microscopy of VDAC1 oligomers in cells treated with CBD at \u0394\u03a8m clamped to -150 mV vs. -170 mV. ---\n    SOURCE: mistral | CONFIDENCE: 0.5\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 33% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1.  How does circadian oscillation of mitochondrial membrane potential (\u0394\u03a8m) alter the conformational state and open probability of VDAC1?\n2.  How does VDAC1's state (e.g., open/high-conductance vs. closed/low-conductance) modulate its binding kinetics (affinity, cooperativity) with CBD?\n3.  What is the specific molecular event (e.g., oligomerization, pore stabilization) that CBD binding to VDAC1 triggers to initiate cytotoxicity, and how is this event threshold-dependent on both CBD concentration and \u0394\u03a8m?\n4.  How do parallel, higher-affinity CBD targets (TRPV1/2) influence the net cellular outcome (protection vs. toxicity) as a function of time-of-day (and thus \u0394\u03a8m)?\n\nKey variables: \u0394\u03a8m(t), VDAC1 P(open), CBD concentration, Hill coefficient (nH), IC50.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: The circadian shift in CBD cytotoxicity is driven by \u0394\u03a8m's control over VDAC1 gating. Depolarization during the circadian trough (~-160 mV) nullifies the intermembrane space Donnan potential, bringing outer membrane voltage near 0 mV, which maximizes VDAC1's open-state probability.\nTYPE: 2\nCONFIDENCE: 0.8\nMECHANISM: VDAC1 gating is directly sensitive to the ~+10-30 mV outer membrane potential established by hyperpolarized \u0394\u03a8m (-180 mV), favoring a closed state; depolarization collapses this potential, favoring the open state.\nFALSIFIABLE BY: Patch-clamp analysis of VDAC1 in proteoliposomes showing P(open) is maximal when the transmembrane potential (equivalent to outer membrane potential) is 0 mV, and decreases at +20 mV.\n\nCLAIM: The open conformation of VDAC1, prevalent at night (depolarized \u0394\u03a8m), exposes allosteric sites that enable cooperative binding of CBD, with a Hill coefficient (nH) of 2.5-3.0.\nTYPE: 2\nCONFIDENCE: 0.7\nMECHANISM: This positive cooperativity explains the sharp drop in the cytotoxic IC50 to sub-Kd levels (3-5 \u03bcM), as initial binding events dramatically increase affinity for subsequent molecules, rapidly triggering a toxic threshold.\nFALSIFIABLE BY: Isothermal titration calorimetry (ITC) measurements of CBD binding to VDAC1 reconstituted in proteoliposomes held at 0 mV (mimicking night) vs. +20 mV (mimicking day), expecting to find nH > 2 only at 0 mV.\n\nCLAIM: The cytoprotective/cytotoxic switch is a target-affinity competition. At all times, low \u03bcM CBD engages high-affinity TRPV1/2 (Kd 2-4 \u03bcM), promoting cytoprotection. Cytotoxicity only occurs when VDAC1 is sensitized at night, allowing cooperative binding at similar concentrations (3-5 \u03bcM) to override the protective signals.\nTYPE: 1\nCONFIDENCE: 0.9\nMECHANISM: Simple competitive pharmacology based on binding affinities and target availability. The state of VDAC1 is the time-dependent variable that determines whether it can compete with TRPV channels.\nFALSIFIABLE BY: Observing that co-treatment with a TRPV1/2 antagonist potentiates CBD cytotoxicity specifically during the hyperpolarized (daytime) phase, but has little effect during the depolarized (nighttime) phase.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n1.  The precise circadian amplitude of \u0394\u03a8m in specific, relevant cell types (e.g., neurons, glioblastoma) is unquantified. The \"healthy\" -180 mV prior is likely the peak, but the trough could be -165 mV or -150 mV, which critically affects VDAC1 gating.\n2.  The molecular identity of the CBD binding site(s) on VDAC1 and how the open/closed conformation alters their accessibility and allosteric communication.\n3.  The stoichiometry of the cytotoxic VDAC1-CBD oligomer. Is it a dimer, a hexamer, or a larger macro-pore, and is this structure stable or transient?\n4.  The direct contribution of TRPV1/2-mediated Ca2+ signaling to mitochondrial \u0394\u03a8m, which could create a feedback loop where CBD's protective action reinforces the daytime, resistant state.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nMeasure CBD dose-response cytotoxicity curves in digitonin-permeabilized cells where mitochondrial \u0394\u03a8m is artificially clamped to -180 mV vs. -160 mV using a potassium chloride and valinomycin buffer system.",
      "claims": [
        {
          "statement": "The circadian shift in CBD cytotoxicity is driven by \u0394\u03a8m's control over VDAC1 gating. Depolarization during the circadian trough (~-160 mV) nullifies the intermembrane space Donnan potential, bringing outer membrane voltage near 0 mV, which maximizes VDAC1's open-state probability.",
          "type": 2,
          "confidence": 0.8,
          "mechanism": "VDAC1 gating is directly sensitive to the ~+10-30 mV outer membrane potential established by hyperpolarized \u0394\u03a8m (-180 mV), favoring a closed state; depolarization collapses this potential, favoring the open state.",
          "falsifiable_by": "Patch-clamp analysis of VDAC1 in proteoliposomes showing P(open) is maximal when the transmembrane potential (equivalent to outer membrane potential) is 0 mV, and decreases at +20 mV."
        },
        {
          "statement": "The open conformation of VDAC1, prevalent at night (depolarized \u0394\u03a8m), exposes allosteric sites that enable cooperative binding of CBD, with a Hill coefficient (nH) of 2.5-3.0.",
          "type": 2,
          "confidence": 0.7,
          "mechanism": "This positive cooperativity explains the sharp drop in the cytotoxic IC50 to sub-Kd levels (3-5 \u03bcM), as initial binding events dramatically increase affinity for subsequent molecules, rapidly triggering a toxic threshold.",
          "falsifiable_by": "Isothermal titration calorimetry (ITC) measurements of CBD binding to VDAC1 reconstituted in proteoliposomes held at 0 mV (mimicking night) vs. +20 mV (mimicking day), expecting to find nH > 2 only at 0 mV."
        },
        {
          "statement": "The cytoprotective/cytotoxic switch is a target-affinity competition. At all times, low \u03bcM CBD engages high-affinity TRPV1/2 (Kd 2-4 \u03bcM), promoting cytoprotection. Cytotoxicity only occurs when VDAC1 is sensitized at night, allowing cooperative binding at similar concentrations (3-5 \u03bcM) to override the protective signals.",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "Simple competitive pharmacology based on binding affinities and target availability. The state of VDAC1 is the time-dependent variable that determines whether it can compete with TRPV channels.",
          "falsifiable_by": "Observing that co-treatment with a TRPV1/2 antagonist potentiates CBD cytotoxicity specifically during the hyperpolarized (daytime) phase, but has little effect during the depolarized (nighttime) phase. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Circadian depolarized \u0394\u03a8m lowers CBD cytotoxic threshold by 3-5x (IC50 from 15 \u03bcM daytime to 3-5 \u03bcM nighttime), enabling sub-Kd (11 \u03bcM) toxicity.\n    MECHANISM: Open VDAC1 at depolarized \u03c8 enhances CBD access/binding cooperativity (Hill coeff >1), accelerating oligomerization and cyt c release.\n    OVERLAP: 5/5 mirrors | CONFIDENCE: 0.581\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] VDAC1 is predominantly open (>80% conductance) at depolarized \u0394\u03a8m (>-160 mV), shifting to closed/low-conductance (<20%) at hyperpolarized (<-170 mV); singular \"grok\" claim validated, \"gemini\" inverted and rejected.\n    SOURCE: grok | CONFIDENCE: 0.9\n  [SINGULAR] Cytoprotective CBD effects (via TRPV1/2, Kd 2-3.7 \u03bcM) dominate at hyperpolarized daytime \u03c8; cytotoxic via VDAC1 flips at depolarized nighttime.\n    SOURCE: grok | CONFIDENCE: 0.65\n  [SINGULAR] VDAC1's voltage-dependent gating operates on **outer mitochondrial membrane (OMM) voltage**, not \u0394\u03a8m directly; however, \u0394\u03a8m influences OMM voltage via the Donnan equilibrium across the intermembrane space. Depolarized \u0394\u03a8m reduces OMM voltage, favoring VDAC1 open state (anion-permeable), while hyperpolarized \u0394\u03a8m increases OMM voltage, promoting VDAC1 closure and oligomerization.\n    SOURCE: claude | CONFIDENCE: 0.55\n  [SINGULAR] At depolarized \u0394\u03a8m (trough, ~-165 mV), VDAC1 remains predominantly open, and CBD at sub-Kd concentrations acts cytoprotectively by modulating metabolite flux (ATP/ADP exchange) without triggering oligomerization.\n    SOURCE: claude | CONFIDENCE: 0.5\n  [SINGULAR] 2**: VDAC1\u2019s open probability is **maximal at \u0394\u03a8m = -180 mV** and decreases linearly with depolarization, reaching 50% closure at **~ -150 mV**. **TYPE**: 2 (novel, testable prediction) **CONFIDENCE**: 0.65 **MECHANISM**: VDAC1\u2019s N-terminal \u03b1-helix acts as a voltage sensor, blocking the pore at depolarized potentials (consistent with [SINGULAR] voltage-sensitive gating). **FALSIFIABLE BY**: Patch-clamp recordings of VDAC1 in proteoliposomes under varying \u0394\u03a8m, or cryo-EM structures at -140 mV vs. -180 mV.\n    SOURCE: mistral | CONFIDENCE: 0.5\n  [SINGULAR] 4**: The transition from cytoprotective to cytotoxic CBD effects occurs at **\u0394\u03a8m < -160 mV**, where VDAC1 oligomerization exceeds a critical threshold (e.g., hexamers). **TYPE**: 3 (speculative, quantitative prediction) **CONFIDENCE**: 0.5 **MECHANISM**: Below -160 mV, VDAC1\u2019s voltage-dependent closure promotes oligomerization, enabling CBD to stabilize large pores and trigger apoptosis. **FALSIFIABLE BY**: Super-resolution microscopy of VDAC1 oligomers in cells treated with CBD at \u0394\u03a8m clamped to -150 mV vs. -170 mV. ---\n    SOURCE: mistral | CONFIDENCE: 0.5\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 33% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION\n1. How does circadian \u0394\u03a8m oscillation (range ~-180 to -160 mV) quantitatively alter VDAC1's conformational state (open vs. closed) and oligomerization propensity?\n2. How does the binding and functional outcome of CBD (Kd 11 \u03bcM for VDAC1) depend on VDAC1's conformational state, and does this create a dose-response threshold shift?\n3. What is the time-dependent mechanism (kinetics vs. equilibrium) governing the switch from cytoprotective (metabolite flux modulation) to cytotoxic (oligomerization, cyt c release) CBD effects?\n4. How do competing low-Kd targets (TRPV1/2, Kd 2-3.7 \u03bcM) influence the net cellular outcome at different \u0394\u03a8m states?\n\nKey variables: \u0394\u03a8m (circadian input), VDAC1 open probability, CBD concentration, VDAC1 oligomerization rate, TRPV1/2 activation state. Relationships: \u0394\u03a8m \u2192 VDAC1 conformation \u2192 CBD binding affinity/cooperativity \u2192 oligomerization kinetics \u2192 cell fate.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\nCLAIM: The",
      "claims": [
        {
          "statement": "The",
          "type": 2,
          "confidence": 0.5,
          "mechanism": "",
          "falsifiable_by": ""
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.05125639772341315,
    "cosine": 0.4728844383731484,
    "jsd": 0.16259219523942603,
    "kappa": 0.8921773142112125,
    "type_distribution": {
      "0": 0.0,
      "1": 0.125,
      "2": 0.6875,
      "3": 0.1875
    },
    "type_01_ratio": 0.125,
    "n_claims_per_model": [
      4,
      4,
      4,
      3,
      1
    ]
  },
  "total_calls": 5
}